Back to News & Media Select Media Coverage Filter by Select Year May 12, 2023 Fierce Biotech: Chutes & Ladders - Former Astellas development head jumps to new Frontier Read Article May 12, 2023 Endpoints News: Astellas president jumps to a new Frontier Read Article May 4, 2023 Fierce Biotech: Next round of KRAS drugs stretch for their 4-minute mile in the footsteps of Amgen and Mirati Read Article February 8, 2023 San Francisco Business Times: Why 2023 is shaping up as a critical year for drug makers Read Article July 20, 2021 The Boston Globe: South San Francisco biotech to set up lab in Boston Read Article July 19, 2021 San Francisco Business Times: With focus on the 'undruggable,' Peninsula biotech raises $88.5M from IPO-minded investors Read Article July 19, 2021 Endpoint News: Months after Amgen's landmark KRAS approval, Chris Varma bags a crossover round for next-gen candidate Read Article December 3, 2020 Fierce Biotech: AbbVie Pays Frontier $55M to Pursue Hard-to-Drug Targets Read Article December 3, 2020 BioSpace: Frontier and AbbVie Team Up Against Elusive Protein Targets Read Article December 2, 2020 BioWorld: In Rugged E3 Space, AbbVie Delivers Frontier Justice – the Good Kind – via $1B-Plus Deal Read Article December 2, 2020 Endpoints News: AbbVie Eyes Cancer, Immunology in Latest Protein Degradation Pact, Handing Frontier Medicines $55M Upfront Read Article November 11, 2019 C&EN: C&EN Names Frontier 2019 10 Start-Ups to Watch Read Article September 23, 2019 FierceBiotech: FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019 Read Article June 26, 2019 BioCentury: Frontier Aims for Previously Unreachable 'Hot Spot' Targets with $67M Series A Read Article June 26, 2019 WSJ Venture Capital: Biotech Entrepreneur Chris Varma Scores $67 Million for Frontier Medicines Read Article June 26, 2019 BioWorld: Frontier Medicines Launches with a $67M Series A Round Read Article
May 12, 2023 Fierce Biotech: Chutes & Ladders - Former Astellas development head jumps to new Frontier Read Article
May 4, 2023 Fierce Biotech: Next round of KRAS drugs stretch for their 4-minute mile in the footsteps of Amgen and Mirati Read Article
February 8, 2023 San Francisco Business Times: Why 2023 is shaping up as a critical year for drug makers Read Article
July 19, 2021 San Francisco Business Times: With focus on the 'undruggable,' Peninsula biotech raises $88.5M from IPO-minded investors Read Article
July 19, 2021 Endpoint News: Months after Amgen's landmark KRAS approval, Chris Varma bags a crossover round for next-gen candidate Read Article
December 3, 2020 Fierce Biotech: AbbVie Pays Frontier $55M to Pursue Hard-to-Drug Targets Read Article
December 2, 2020 BioWorld: In Rugged E3 Space, AbbVie Delivers Frontier Justice – the Good Kind – via $1B-Plus Deal Read Article
December 2, 2020 Endpoints News: AbbVie Eyes Cancer, Immunology in Latest Protein Degradation Pact, Handing Frontier Medicines $55M Upfront Read Article
September 23, 2019 FierceBiotech: FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019 Read Article
June 26, 2019 BioCentury: Frontier Aims for Previously Unreachable 'Hot Spot' Targets with $67M Series A Read Article
June 26, 2019 WSJ Venture Capital: Biotech Entrepreneur Chris Varma Scores $67 Million for Frontier Medicines Read Article